Prominent heart failure cardiologist Dr. William Abraham to play pivotal role in the advancement of the Carillon Mitral Contour System® to heart failure patients with FMR.
Cardiac Dimensions®, a leader in transcatheter therapies for heart failure, announced today the appointment of William T. Abraham, MD, as Chief Medical Officer. A globally recognized expert in heart failure and device-based therapies, Dr. Abraham will help lead the company’s clinical and regulatory strategies as it advances toward U.S. regulatory approval and continues to expand European commercial sales of the Carillon Mitral Contour System®.
Dr. Abraham most recently served as the Chief Medical Officer at V-Wave Ltd., where he led the U.S. pivotal trial and played a key role in advancing the company’s transcatheter interatrial shunt therapy, culminating in a significant heart failure-focused acquisition by Johnson & Johnson. Dr. Abraham is a College of Medicine Distinguished Professor at The Ohio State University, where he was the Director of the Division of Cardiovascular Medicine for more than 15 years, and has published over 650 peer-reviewed papers. He is internationally known for his leadership in advancing heart failure treatments, including cardiac resynchronization therapy, remote hemodynamic monitoring, and transcatheter valve repair. Dr. Abraham has also served as national or global principal investigator on more than 50 multicenter trials, including important trials within the mitral valve space.
“We are delighted to welcome Dr. Abraham to the Cardiac Dimensions leadership team,” said Rick Wypych, President and CEO of Cardiac Dimensions. “Bill’s impact on the heart failure field is unmatched. His input and influence on the Carillon therapy will help drive the success and adoption of this much-needed therapy. In addition, his experience with large-scale clinical trials and regulatory pathways will be instrumental to the completion of our pivotal U.S. landmark study – The EMPOWER Trial.”
“I’ve spent my career working to bring novel and impactful therapies to people living with heart failure,” said Dr. Abraham. “What drew me to Cardiac Dimensions is the Carillon therapy’s unique position in the heart failure treatment paradigm. It offers a physiologically elegant approach to reducing mitral regurgitation, preserving future treatment options, and modifying the disease process itself. I’m particularly encouraged by the consistent data showing favorable atrial and ventricular remodeling, symptom improvement, and a excellent safety profile – even in patients with proportionate MR who are often excluded from other therapies.”
The Carillon Mitral Contour System has received CE Mark and is available for sale in Europe and other countries that recognize CE Mark.
Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!
